Asian Journal of Cardiology Research

The Management of Dyslipidemia in Patients with Diabetes Mellitus Type 2 Using Ayurveda Based Treatment: A Case Study

Archana Manish Wajage *

Chinchwad Clinic, Pune, Maharashtra, India.

Sadik Khan

Madhavbaug Cardiac Clinic and Hospital, Thane, Maharashtra, India.

*Author to whom correspondence should be addressed.

---

Abstract

Background: The biggest cause of death worldwide is dyslipidemia, a significant risk factor for coronary heart disease (CHD). Additionally, individuals with type 2 diabetes mellitus (T2DM) are at high risk for cardiovascular comorbidities. Currently available allopathic treatments are associated with several side effects. Ayurveda can play an effective role in reducing this risk factor by preventing the impact of Dyslipidemia.

Aim: This case study aimed to analyze the effectiveness of Virechana karma, ayurvedic medicines, and lifestyle modifications in the management of dyslipidemia in patients with Diabetes Mellitus 2.

Materials and Methods: Three patients with the condition of Dyslipidemia and other comorbidities like diabetes, Obesity, hypertension, heart diseases, hypothyroidism, etc. were administrated with Virechana karma, ayurvedic medicines, and lifestyle modifications. The treatment's effectiveness was assessed by comparing the whole lipid profile at the end of the course of treatment and after the follow-up period to the baseline score.

Results: After therapy and after the follow-up, the lipid profiles of all three patients revealed statistically significant results. The levels of total cholesterol, low-density lipoprotein, and triglyceride significantly decreased and levels of high-density lipoprotein  increased after Virechana karma. Additionally, BMI, sugar levels, and thyroid profile also improved.

Conclusion: Virechana karma, a traditionally used ayurvedic treatment was found to be useful in the management of dyslipidemia with Diabetes Mellitus 2. Randomized control trial with larger sample size is warranted to extrapolate the findings of current case study.

Keywords: Sasneh virechana, dyslipidemia, diabetes mellitus, case report, total cholesterol, HDL - cholesterol, lipid profile, BMI

---

---

---

References

Parhofer KG. Interaction between glucose and lipid metabolism: More than diabetic dyslipidemia. Diabetes Metab J. 2015;39(5):353-62. Epub 2015 Oct 22. PMID: 26566492; PMCID: PMC4641964.

DOI: 10.4093/dmj.2015.39.5.353

Ghose T. Statins in dyslipidemia. Handbook of Lipidology. 2016:105.

Dhurve R. A Case of dyslipidemia (medoroga) successfully managed by Virechana Karma: A Case Study. International Journal of Ayurveda. 2020:22-4.

Million death study investigators. Preliminary report on causes of death in India. 2001–2003.

Pooja BA, Santosh Kumar Bhatted. A standard controlled clinical study on Virechana Karma and LekhanaBasti in the management of dyslipidemia (medoroga), Ayu. 2016;37(1): 32–37.

Farmer JA, Torre-Amione G. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf. 2000;23:197–213.

McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained-vs immediate-release niacin in hypercholesterolemia patients. JAMA. 1994;271:672–7.

Singh SK, Rajoria K, Swami P. Ayurvedic approach in management of dyslipidemia: A case study. JoAYUSH. 2015;4(3):33-36.

Kanungo SK, Panda DS, Swain SR, Barik BB, Tripathi DK. Comparative evaluation of hypolipidemic activity of some marketed herbal formulations in triton induced hyperlipidemic rats. Pharmacologyonline. 2007;3:211-21.